Ankit R. Patel, H. B. Patel, V. Sarvaiya, R.D. Singh, H. Patel, Sanjay Vaghela, Sheen Tukra, S. Mody
{"title":"Pharmacokinetics of Marbofloxacin Following Oral Administration in Lactic Acid Pretreated Broiler Chickens","authors":"Ankit R. Patel, H. B. Patel, V. Sarvaiya, R.D. Singh, H. Patel, Sanjay Vaghela, Sheen Tukra, S. Mody","doi":"10.18805/ajdfr.dr-2046","DOIUrl":null,"url":null,"abstract":"Background: It is hypothesized that feeding lactic acid as a feed additive has the potential to alter the pharmacokinetics of many antimicrobial drugs being used for the treatment of infectious disease in general and marbofloxacin in particular; leading to either increased or decreased efficiency. Hence, the present study was planned to explore the effects of lactic acid pre-treatment on the pharmacokinetics of marbofloxacin after oral administration in broiler chickens. Methods: The pharmacokinetics of marbofloxacin was investigated following single dose oral administration (5 mg/kg) in lactic acid pre-treated (8 gm/l each, oral, 10 days) broiler chickens. The plasma concentration of marbofloxacin was determined by ultra-high-performance liquid chromatography to workout pharmacokinetic profile of marbofloxacin using non compartment model. Result: The AUC (area under curve) of marbofloxacin declined from 14.70 ìg·h/mL to 6.16 ìg·h/mL after pre-treatment of lactic acid. Similarly, the average values of maximum plasma concentration (Cmax) of drug decreased from 2.11 ìg/mL to 0.98 ìg/mL and mean body clearance (ClB) increased from 0.47 L/h/kg to 1.03 L/h/kg. The average elimination half-lives (t½â) of marbofloxacin before and after pre-treatment with lactic acid were 4.89 h and 2.81 h, respectively. Furthermore, the investigation revealed alteration of pharmacokinetic parameters evident in lactic acid pre-treated broiler chickens (as compared to non pre-treated birds) requiring adjustment of dosage regimens.","PeriodicalId":89171,"journal":{"name":"Journal of dairying, foods & home sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of dairying, foods & home sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18805/ajdfr.dr-2046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: It is hypothesized that feeding lactic acid as a feed additive has the potential to alter the pharmacokinetics of many antimicrobial drugs being used for the treatment of infectious disease in general and marbofloxacin in particular; leading to either increased or decreased efficiency. Hence, the present study was planned to explore the effects of lactic acid pre-treatment on the pharmacokinetics of marbofloxacin after oral administration in broiler chickens. Methods: The pharmacokinetics of marbofloxacin was investigated following single dose oral administration (5 mg/kg) in lactic acid pre-treated (8 gm/l each, oral, 10 days) broiler chickens. The plasma concentration of marbofloxacin was determined by ultra-high-performance liquid chromatography to workout pharmacokinetic profile of marbofloxacin using non compartment model. Result: The AUC (area under curve) of marbofloxacin declined from 14.70 ìg·h/mL to 6.16 ìg·h/mL after pre-treatment of lactic acid. Similarly, the average values of maximum plasma concentration (Cmax) of drug decreased from 2.11 ìg/mL to 0.98 ìg/mL and mean body clearance (ClB) increased from 0.47 L/h/kg to 1.03 L/h/kg. The average elimination half-lives (t½â) of marbofloxacin before and after pre-treatment with lactic acid were 4.89 h and 2.81 h, respectively. Furthermore, the investigation revealed alteration of pharmacokinetic parameters evident in lactic acid pre-treated broiler chickens (as compared to non pre-treated birds) requiring adjustment of dosage regimens.